Abstract
The association of hypertension and coronary heart disease is a frequent one. There are several pathophysiologic mechanisms which link both diseases. Hypertension induces endothelial dysfunction, exacerbates the atherosclerotic process and it contributes to make the atherosclerotic plaque more unstable. Left ventricular hypertrophy, which is the usual complication of hypertension, promotes a decrease of ‘coronary reserve’ and increases myocardial oxygen demand, both mechanisms contributing to myocardial ischaemia. From a clinical point of view hypertensive patients should have a complete evaluation of risk factors for atherosclerosis, damage of arterial territories other than the coronary one, and of the extension and severity of coronary artery involvement. It is important to emphasise that complications and mortality of patients suffering a myocardial infarction are greater in hypertensive patients. Treatment should be aimed to achieve optimal values of blood pressure, and all the strategies to treat coronary heart disease should be considered on an individual basis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Assmann G, Schulte H . The Prospective Cardio-vascular Munster (PROCAM) study: prevalence of hyperlipidemia inpatients with hypertension and/or diabetes mellitus and the relationship to coronary heart disease Am Heart J 1988 116: 1713–1724
Scandivanian Simvastatin Survival Study group. Randomized trial of cholesterol lowering in 4444patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4 S) Lancet 1994 344: 11383–1389
Sacks FM et al. The effect of pravastatin on coronary events after myocardial infarction inpatients with average cholesterol levels: the cholesterol and recurrent events (CARE) trial N Engl J Med 1996 335: 1001–1009
The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin inpatients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 1998 339: 1349–1357
Stamler J, Stamler R, Neaton JD . Blood pressure, systolic and diastolic, and cardiovascular risks. US population data Arch Int Med 1993 153: 598–615
MacMahon S et al. Blood pressure,stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias Lancet 1990 335: 765–774
O'Donell CJ et al. Hypertension and borderlineisolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians Circulation 1997 95: 1132–1137
Chobanian AV, Alexander RW . Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications Arch Int Med 1996 156: 1952–1956
DeFronzo RA, Ferrannini E . Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease Diabetes Care 1991 14: 173–194
Strauer BE . The concept of coronary flow reserve J Cardiovasc Pharmacol 1992 19 (Suppl 5): 67–80
Chilian WM et al. Thyroxine-induced left ventricular hypertrophy in the rat: anatomical and physiological evidence for angiogenesis Cir Res 1985 57: 591–598
Tomanek RJ et al. Morphometry of canine coronary arteries, arterioles, and capillaries during hypertension and left ventricular hypertrophy Circ Res 1986 58: 38–46
Hamasaki S et al. Attenuated coronary flow reserve and vascular remodelling inpatients with hypertension and left ventricular hypertrophy J Am Coll Cardiol 2000 35: 1654–1660
Strauer BE . Coronary hemodynamics in hypertensive heart disease. Basic concepts, clinical consequences, and experimental analysis of regression of hypertyensive microangiopathy Am J Med 1988 84 (Suppl 3A): 45–54
Ito N et al. Remodelling of microvessels by coronary hypertension or cardiac hypertrophy J Mol Cell Cardiol 1994 26: 49–59
Isoyama S . Myocardial hypertrophy and coronary circulation before and after relief of pressure overload. In: Maruyama Y, Janicki JS (eds) Cardiovascular Remodelling and Functional Interaction Springer-Verlag: Tokyo, Japan 1996 33–46
Isoyama S, Ito N, Satoh K, Takishima T . Collagen deposition and the reversal of coronary reserve in cardiac hypertrophy Hypertension 1992 20: 491–500
Schawrzkopff B et al. Structural and functional alterations of the intramyocardial coronary arterioles inpatients with arterial hypertension Circulation 1993 88: 993–1003
Tanaka M et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts and hearts with hypertensive cardiomyopathy Circulation 1987 75: 1130–1139
Ito N, Isoyama S, Tokahashi T, Yakishima T . Coronary dilator reserve and morphological changes after relief of pressure overload rats J Mol Cell Cardiol 1993 25: 3–14
Nitenberg A, Antony I . Epicardial coronary arteries are not adequately sized in hypertensivepatients J Am Coll Cardiol 1996 27: 115–123
Kannel WB, Cobb J . Left ventricular hypertrophy and mortality: results from the Framingham Study Cardiology 1992 81: 291–298
MacMahon S, Rodgers A . The effects of blood pressure reduction in olderpatients: an overview of five randomized controlled trials in elderly hypertensives Clin Exp Hypertens 1993 15: 967–978
Patsy BM et al. Health outcomes associated with antihypertensive therapies used as first line agents: a systematic review and metaanylisis JAMA 1997 277: 739–745
Hamsson L et al. Effects of intensive blood pressure lowering and low dose aspirin inpatients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group Lancet 1998 351: 1755–1762
Sullivan JM, Francis ChK . Management of hypertensivespatients with ischemic heart disease. In: Izzo JL, Black HR (eds) Hypertension Primer, 2nd edn Lippincott Williams and Wilkins: Maryland 1999 398–401
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Escobar, E. Hypertension and coronary heart disease. J Hum Hypertens 16 (Suppl 1), S61–S63 (2002). https://doi.org/10.1038/sj.jhh.1001345
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001345
Keywords
This article is cited by
-
The risk of hypertension among child brides and adolescent mothers at age 20 s, 30 s, and 40 s: Evidence from India
Journal of Human Hypertension (2022)
-
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Nature Reviews Drug Discovery (2022)
-
Bladder paraganglioma: basic characteristics and new perspectives on perioperative management
World Journal of Urology (2022)
-
Hydrochlorothiazide and Indapamide bind the NADPH binding site of bacterial Dihydrofolate Reductase: results of an in-silico study and their implications
In Silico Pharmacology (2020)
-
Upregulation of Circulating Cardiomyocyte-Enriched miR-1 and miR-133 Associate with the Risk of Coronary Artery Disease in Type 2 Diabetes Patients and Serve as Potential Biomarkers
Journal of Cardiovascular Translational Research (2019)